Marston L, Nazareth I, Petersen I, Walters K, Osborn DP (2014) Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open 4(12):e006135. https://doi.org/10.1136/bmjopen-2014-006135

Article  PubMed  PubMed Central  Google Scholar 

Badcock JC, Larøi F, Kamp K, Kelsall-Foreman I, Bucks RS, Weinborn M, Begemann M, Taylor JP, Collerton D, O’Brien JT, El Haj M, Ffytche D, Sommer IE (2020) Hallucinations in older adults: a practical review. Schizophr Bull 46(6):1382–1395. https://doi.org/10.1093/schbul/sbaa073

Article  PubMed  PubMed Central  Google Scholar 

Hálfdánarson Ó, Zoëga H, Aagaard L, Bernardo M, Brandt L, Fusté AC, Furu K, Garuoliené K, Hoffmann F, Huybrechts KF, Kalverdijk LJ, Kawakami K, Kieler H, Kinoshita T, Litchfield M, López SC, Machado-Alba JE, Machado-Duque ME, Mahesri M, Nishtala PS, Pearson SA, Reutfors J, Saastamoinen LK, Sato I, Schuiling-Veninga CCM, Shyu YC, Skurtveit S, Verdoux H, Wang LJ, Yahni CZ, Bachmann CJ (2017) International trends in antipsychotic use: a study in 16 countries, 2005–2014. Eur Neuropsychopharmacol 27(10):1064–1076. https://doi.org/10.1016/j.euroneuro.2017.07.001

Article  CAS  PubMed  Google Scholar 

Roberts R, Neasham A, Lambrinudi C, Khan A (2018) A quantitative analysis of antipsychotic prescribing trends for the treatment of schizophrenia in England and Wales. JRSM Open 9(4):2054270418758570. https://doi.org/10.1177/2054270418758570

Article  PubMed  PubMed Central  Google Scholar 

Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47(1):27–38

Article  PubMed  Google Scholar 

Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17(12):1206–1227. https://doi.org/10.1038/mp.2012.47

Article  CAS  PubMed  Google Scholar 

Correll CU, Lencz T, Malhotra AK (2011) Antipsychotic drugs and obesity. Trends Mol Med 17(2):97–107. https://doi.org/10.1016/j.molmed.2010.10.010

Article  CAS  PubMed  Google Scholar 

Salvi V, Barone-Adesi F, D’Ambrosio V, Albert U, Maina G (2016) High H1-affinity antidepressants and risk of metabolic syndrome in bipolar disorder. Psychopharmacology 233(1):49–56. https://doi.org/10.1007/s00213-015-4085-9

Article  CAS  PubMed  Google Scholar 

De Hert M, Detraux J, van Winkel R, Yu W, Correll CU (2012) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8(2):114–126. https://doi.org/10.1038/nrendo.2011.156

Article  CAS  Google Scholar 

Correll CU (2008) Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 47(1):9–20. https://doi.org/10.1097/chi.0b013e31815b5cb1

Article  PubMed  Google Scholar 

Damba JJ, Bodenstein K, Lavin P, Drury J, Sekhon H, Renoux C, Trinh E, Rej S, Greenway KT (2022) Psychotropic drugs and adverse kidney effects: a systematic review of the past decade of research. CNS Drugs 36(10):1049–1077. https://doi.org/10.1007/s40263-022-00952-y

Article  CAS  PubMed  Google Scholar 

Jiang Y, McCombs JS, Park SH (2017) A retrospective cohort study of acute kidney injury risk associated with antipsychotics. CNS Drugs 31(4):319–326. https://doi.org/10.1007/s40263-017-0421-4

Article  CAS  PubMed  Google Scholar 

Hwang YJ, Dixon SN, Reiss JP, Wald R, Parikh CR, Gandhi S, Shariff SZ, Pannu N, Nash DM, Rehman F, Garg AX (2014) Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med 161(4):242–248. https://doi.org/10.7326/m13-2796

Article  PubMed  Google Scholar 

Nian-Sheng T, Yung-Ho H, Shinn-Ying H, Yu-Ching K, Hua-Chin L, Yun-Ju Y, Hong-An C, Wen-Liang C, William Cheng-Chung C, Hui-Ling H (2015) Is schizophrenia associated with an increased risk of chronic kidney disease? A nationwide matched-cohort study BMJ Open 5(1):e006777. https://doi.org/10.1136/bmjopen-2014-006777

Article  Google Scholar 

Hsien-Yi W, Charles Lung-Cheng H, Feng IJ, Hui-Chun T (2018) Second-generation antipsychotic medications and risk of chronic kidney disease in schizophrenia: population-based nested case–control study. BMJ Open 8(5):e019868. https://doi.org/10.1136/bmjopen-2017-019868

Article  Google Scholar 

Cohen R, Wilkins KM, Ostroff R, Tampi RR (2007) Olanzapine and acute urinary retention in two geriatric patients. Am J Geriatr Pharmacother 5(3):241–246. https://doi.org/10.1016/j.amjopharm.2007.09.003

Article  CAS  PubMed  Google Scholar 

Johnson D, Philip AZ, Joseph DJ, Varghese R (2007) Risperidone-induced neuroleptic malignant syndrome in neurodegenerative disease: a case report. Prim Care Companion J Clin Psychiatry 9(3):237–238. https://doi.org/10.4088/pcc.v09n0311f

Article  PubMed  PubMed Central  Google Scholar 

Ahuja N, Palanichamy N, Mackin P, Lloyd A (2010) Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature. J Psychopharmacol 24(1):125–130. https://doi.org/10.1177/0269881108096901

Article  CAS  PubMed  Google Scholar 

Højlund M, Lund LC, Herping JLE, Haastrup MB, Damkier P, Henriksen DP (2020) Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study. BMJ Open 10(8):e038247. https://doi.org/10.1136/bmjopen-2020-038247

Article  PubMed  PubMed Central  Google Scholar 

El-Saifi N, Moyle W, Jones C, Tuffaha H (2016) Quetiapine safety in older adults: a systematic literature review. J Clin Pharm Ther 41(1):7–18. https://doi.org/10.1111/jcpt.12357

Article  CAS  PubMed  Google Scholar 

Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Retrieved from https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp on 1st Decemeber 2023.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188. https://doi.org/10.1016/0197-2456(86)90046-2

Article  CAS  PubMed  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928

Article  PubMed  PubMed Central  Google Scholar 

Review Manager (RevMan) (2020) [Computer program]. Version 5.4.1 The Cochrane Collaboration

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https://doi.org/10.1136/bmj.b2535

Article  PubMed  PubMed Central  Google Scholar 

Ryan PB, Schuemie MJ, Ramcharran D, Stang PE (2017) Atypical antipsychotics and the risks of acute kidney injury and related outcomes among older adults: a replication analysis and an evaluation of adapted confounding control strategies. Drugs Aging 34(3):211–219. https://doi.org/10.1007/s40266-016-0430-x

Article  CAS  PubMed  Google Scholar 

Wang HY, Huang CL, Feng IJ, Tsuang HC (2018) Second-generation antipsychotic medications and risk of chronic kidney disease in schizophrenia: population-based nested case-control study. BMJ Open 8(5):e019868. https://doi.org/10.1136/bmjopen-2017-019868

Article  PubMed  PubMed Central  Google Scholar 

Sharon R, Lange T, Aakjær M, Brøgger Kristiansen S, Baltzer Houlind M, Andersen M (2022) Incidence of hospital contacts with acute kidney injury after initiation of second-generation antipsychotics in older adults: a Danish population-based cohort study. Eur J Clin Pharmacol 78(8):1341–1349. https://doi.org/10.1007/s00228-022-03339-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Correll CU, Detraux J, De Lepeleire J, De Hert M (2015) Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 14(2):119–136. https://doi.org/10.1002/wps.20204

Article  PubMed  PubMed Central